Jazz Pharmaceuticals PLC $JAZZ Stake Raised by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP increased its stake in Jazz Pharmaceuticals by 141.5%, owning approximately $12.53 million worth of shares as of the latest SEC filing.
• CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals, decreasing his ownership stake by 0.23% to 436,973 shares valued at around $47 million.
• Jazz Pharmaceuticals reported a negative earnings per share of ($8.25) for the recent quarter, missing estimates and marking a significant year-over-year decline from $5.30 per share.

Wellington Management Group LLP grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 141.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,962 shares of the specialty pharmaceutical company's stock after purchasing an additional 59,159 shares during the quarter. Wellington Management Group LLP owned approximately 0.16% of Jazz Pharmaceuticals worth $12,534,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in JAZZ. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after buying an additional 315,608 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Jazz Pharmaceuticals by 4.7% during the first quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock worth $206,343,000 after buying an additional 74,501 shares during the period. Vestal Point Capital LP boosted its stake in Jazz Pharmaceuticals by 8.3% during the fourth quarter. Vestal Point Capital LP now owns 975,000 shares of the specialty pharmaceutical company's stock worth $120,071,000 after buying an additional 75,000 shares during the period. Finally, Perpetual Ltd boosted its stake in Jazz Pharmaceuticals by 60.2% during the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after buying an additional 357,784 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $1.62 during mid-day trading on Monday, reaching $127.75. 675,563 shares of the company's stock were exchanged, compared to its average volume of 904,550. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a market capitalization of $7.75 billion, a PE ratio of -18.98, a price-to-earnings-growth ratio of 8.04 and a beta of 0.24. The business's fifty day simple moving average is $114.48 and its 200-day simple moving average is $116.97. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the business posted $5.30 EPS. Jazz Pharmaceuticals's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Piper Sandler reissued an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday. Finally, The Goldman Sachs Group raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $178.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.